PHARMACEUTICAL ECONSULTING A/S: Financial statements 2023
CVR: 30815378
Source: annual report 2023, Danish Business Authority
01/10/2022 – 30/09/2023
PHARMACEUTICAL ECONSULTING A/S (CVR 30815378) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 5,578,646 and a net result of DKK -383,631 compared with DKK 779,620 the year before. That is a decrease of 17.7% compared with the year before. Equity in the 2023 report amounted to DKK 6,863,418. The solvency ratio was 85.9%. The company had 8 employees in the financial year.
- Gross Profit
- DKK 5,578,646
- Profit/Loss
- DKK -383,631
- Equity
- DKK 6,863,418
- Total Assets
- DKK 7,990,634
- Employees
- 8
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 5.6M | -384K | 6.9M | 8 |
| 2022 | - | 6.8M | 780K | 7.2M | 8 |
| 2021 | - | 8.3M | 2.4M | 6.5M | 5 |
| 2020 | - | 6.9M | 2.3M | 4M | 4 |
| 2019 | - | 5.3M | 1.2M | 2.7M | 4 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
PHARMACEUTICAL ECONSULTING A/S has published its annual report for 2022. Gross profit came to DKK 6,778,724, and the net result was DKK 779,620.
As of March 27, 2023, Optimal Revision Godkendt Revisionsvirksomhed has been appointed auditor of PHARMACEUTICAL ECONSULTING A/S.
About PHARMACEUTICAL ECONSULTING A/S
PHARMACEUTICAL ECONSULTING A/S is a Danish company of the type Aktieselskab based in Glostrup, founded in 2007. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Steen Otto Rugaard. The board consists of Pernille Laurberg Rugaard (chair), Hanne Laurberg Olesen and Steen Otto Rugaard. The company is owned by RUGAARD HOLDING ApS. The company has 9 employees (2026). In 2025, the company reported a gross profit of DKK 6,113,709 and a net result of DKK -1,066,960 compared with DKK -643,853 the year before. Equity in the 2025 report amounted to DKK 5,152,605.